Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension

Am J Cardiol. 1984 Nov 1;54(8):1015-9. doi: 10.1016/s0002-9149(84)80136-8.


Two groups of patients with uncomplicated systemic hypertension were studied. Group 1 included 11 patients who had overt hypokalemia with diuretic drug treatment, and group 2 included 11 patients who remained normokalemic. After baseline studies without treatment were performed, both groups received hydrochlorothiazide, 50 mg twice daily. Plasma potassium (PK) was significantly reduced within the first day of treatment and stabilized by day 7 in both groups. The average decrease in PK was 1.0 +/- 0.1 mEq/liter (p less than 0.01) in the first group and 0.6 +/- 0.2 mEq/liter (p less than 0.01) in the second group. Cumulative losses of K were approximately 200 mEq in the hypokalemic group and were minimal in the normokalemic group as assessed by 24-hour urinary collections. Patients in the hypokalemic group also had a greater reduction in body weight and blood pressure. Supplementation with KCl, 96 mEq/day, or triamterene, 200 mg/day, in 9 hypokalemic patients resulted in an increase of PK to approximately 3.5 mEq/liter leveling off by day 7, and a cumulative K retention of approximately 200 mEq. Thus, overt thiazide-induced hypokalemia was associated with small and biologically unimportant losses of K from body stores. With replacement therapy the estimated amount of retained K was also small.

MeSH terms

  • Blood Pressure / drug effects
  • Body Weight / drug effects
  • Creatinine / blood
  • Humans
  • Hydrochlorothiazide / adverse effects
  • Hydrochlorothiazide / therapeutic use*
  • Hypertension / blood*
  • Hypertension / drug therapy
  • Hypertension / urine
  • Hypokalemia / chemically induced
  • Middle Aged
  • Potassium / blood*
  • Potassium / urine
  • Sodium / urine
  • Triamterene / adverse effects
  • Triamterene / therapeutic use*


  • Hydrochlorothiazide
  • Sodium
  • Creatinine
  • Potassium
  • Triamterene